Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

C. Campbell · SciRah

Researcher profile · Semantic Scholar

C. Campbell

Share profile

C. Campbell — researcher profile on SciRah

h-index: 18
Works: 43
Citations: 2,936

Most-cited papers

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
A. Tutt, J. Garber, B. Kaufman, G. Viale +35 more
2021New England Journal of Medicine1,390 citations Open access
Semantic Scholar
Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
R. Salgado, C. Denkert, C. Campbell, P. Savas +11 more
2015JAMA Oncology574 citations Open access
Semantic Scholar
Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials.
C. O'Sullivan, I. Bradbury, C. Campbell, M. Spielmann +12 more
2015Journal of Clinical Oncology105 citations Open access
Semantic Scholar
Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial
F. Rothé, M. J. Silva, D. Venet, C. Campbell +19 more
2019Clinical Cancer Research101 citations Open access
Semantic Scholar
Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients
M. Lambertini, C. Campbell, J. Bines, L. Korde +18 more
2018Journal of the National Cancer Institute98 citations Open access
Semantic Scholar
High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab
M. Scaltriti, P. Nuciforo, I. Bradbury, J. Sperinde +18 more
2014Clinical Cancer Research80 citations
Semantic Scholar
Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2–positive early breast cancer: Analysis from the NeoALTTO (BIG 1‐06) and ALTTO (BIG 2‐06) trials
M. Lambertini, S. Martel, C. Campbell, S. Guillaume +13 more
2018Cancer67 citations Open access
Semantic Scholar
Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06)
N. Pondé, I. Bradbury, M. Lambertini, M. Ewer +20 more
2017Breast Cancer Research and Treatment56 citations Open access
Semantic Scholar
Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer.
K. Gelmon, S. O'Reilly, A. Tolcher, C. Campbell +9 more
1996Journal of Clinical Oncology55 citations
Semantic Scholar
Lucitanib for the Treatment of HR+/HER2− Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study
R. Hui, A. Pearson, J. Cortés, C. Campbell +19 more
2019Clinical Cancer Research52 citations Open access
Semantic Scholar
Carboplatin, ifosfamide and etoposide with mid-course vincristine and thoracic radiotherapy for 'limited' stage small cell carcinoma of the bronchus.
N. Thatcher, Michael J. Lind, Ronald Stout, C. Payne +3 more
1989British Journal of Cancer51 citations Open access
Semantic Scholar
Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial.
I. Krop, J. Paulson, C. Campbell, A. Kiermaier +12 more
2019Journal of Clinical Oncology43 citations
Semantic Scholar
Plasmablastic lymphoma: a new subcategory of human immunodeficiency virus-related non-Hodgkin's lymphoma.
R. S. Brown, C. Campbell, S. Lishman, M. Spittle +1 more
1998Clinics in oncology43 citations
Semantic Scholar
Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2–06) randomized clinical trial
M. Lambertini, C. Campbell, R. Gelber, G. Viale +14 more
2019Breast Cancer Research and Treatment41 citations Open access
Semantic Scholar
OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer.
A. Tutt, J. Garber, B. Kaufman, G. Viale +16 more
2021Journal of Clinical Oncology33 citations
Semantic Scholar
Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial.
A. Sonnenblick, E. de Azambuja, D. Agbor-tarh, I. Bradbury +15 more
2016Journal of the National Cancer Institute25 citations Open access
Semantic Scholar
Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies
J. Robertson, A. Di Leo, S. Johnston, S. Chia +5 more
2021npj Breast Cancer24 citations Open access
Semantic Scholar
Delivery of full dose CHOP chemotherapy to elderly patients with aggressive non-Hodgkin's lymphoma without G-CSF support.
C. Campbell, Carol A. Sawka, Edmée Franssen, N. Berinstein
1999Leukemia and Lymphoma23 citations
Semantic Scholar
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO
S. Di Cosimo, C. Campbell, H. A. Azim, G. Galli +17 more
2017European Journal of Cancer18 citations Open access
Semantic Scholar
Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial
H. Yamauchi, M. Toi, S. Takayama, Seigo Nakamura +6 more
2023Breast Cancer15 citations Open access
Semantic Scholar
Meta-analyses of phase 3 randomised controlled trials of third generation aromatase inhibitors versus tamoxifen as first-line endocrine therapy in postmenopausal women with hormone receptor-positive advanced breast cancer.
J. Robertson, R. Paridaens, J. Lichfield, I. Bradbury +1 more
2021European Journal of Cancer15 citations Open access
Semantic Scholar
A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer.
K. Gelmon, A. Tolcher, S. O'Reilly, C. Campbell +7 more
1998Annals of Oncology11 citations Open access
Semantic Scholar
On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome.
S. Luen, G. Griguolo, P. Nuciforo, C. Campbell +15 more
2019Journal of Clinical Oncology8 citations
Semantic Scholar
A meta-analysis of clinical benefit rates for fulvestrant 500 mg vs. alternative endocrine therapies for hormone receptor-positive advanced breast cancer
J. Robertson, Zefei Jiang, A. Di Leo, S. Ohno +4 more
2019Breast Cancer7 citations Open access
Semantic Scholar
Circulating tumor DNA in HER2 amplified breast cancer: a translational research substudy of the NeoALTTO phase 3 trial
F. Rothé, M. J. Silva, D. Venet, C. Campbell +22 more
20192 citations
Semantic Scholar
Lucitanib for the treatment of HR+ HER2- metastatic breast cancer (MBC) patients (pts): Results from the multicohort phase II FINESSE trial.
R. Hui, A. Pearson, J. C. Castán, C. Campbell +16 more
2018Annals of Oncology2 citations Open access
Semantic Scholar
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial.
J. Garber, D. Cameron, C. Campbell, G. Yothers +63 more
2026Annals of Oncology1 citations Open access
Semantic Scholar
Abstract GS4-09: Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer
P. Ganz, H. Bandos, Tanja Spanic, S. Friedman +21 more
2022Cancer Research1 citations
Semantic Scholar
Markers of steroid receptor, kinase signalling pathways and Ki-67 expression in relation to tamoxifen sensitivity and resistance
C. Campbell, J. Mathew, I. Ellis, I. Bradbury +6 more
2020Translational Breast Cancer Research1 citations Open access
Semantic Scholar
Abstract PD3-03: Circulating tumor DNA in HER2 amplified breast cancer: A translational research substudy of the NeoALTTO phase 3 trial
M. Ignatiadis, M. J. Silva, C. Campbell, I. Bradbury +17 more
20181 citations
Semantic Scholar
Abstract P4-21-09: Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2 positive early breast cancer (BIG 1-06)
E. de Azambuja, I. Bradbury, M. Ewer, C. Campbell +12 more
20171 citations
Semantic Scholar
Postmastectomy radiation therapy in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer: a retrospective exploratory cohort analysis of the adjuvant lapatinib and/or trastuzumab treatment optimization (ALTTO) trial [BIG 2-06/NCCTG N063D (Alliance)]
M. D. De Santis, C. Campbell, Faye Samy, F. De Rose +16 more
2026EClinicalMedicine0 citations Open access
Semantic Scholar
Correction: Adjuvant olaparib in the subset of patients from Japan with BRCA1- or BRCA2-mutated high-risk early breast cancer from the phase 3 OlympiA trial
H. Yamauchi, M. Toi, S. Takayama, Seigo Nakamura +6 more
2023Breast Cancer0 citations Open access
Semantic Scholar
Abstract P4-13-13: Meta-analyses of visceral versus non-visceral metastases treated by AI & SERD agents as 2ndline endocrine therapy (ET) for HR+ breast cancer (BC)
J. Robertson, A. Di Leo, S. Johnston, S. Chia +3 more
2019Poster Session Abstracts0 citations
Semantic Scholar
P140 Microbial community composition in cystic fibrosis patients during treatment for pulmonary exacerbation
G. Einarsson, L. Sherrard, Bryan T. Zorn, J. Hatch +16 more
2019Journal of Cystic Fibrosis0 citations Open access
Semantic Scholar
Abstract P2-08-14: Dissecting the effect of hormone receptor (HR) status expression in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Exploratory analysis from the ALTTO (BIG 2-06) trial
M. Lambertini, C. Campbell, RD Gelber, G. Viale +15 more
2019Poster Session Abstracts0 citations
Semantic Scholar
Pregnancies during and following trastuzumab (T) and/or lapatinib (L) in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials.
M. Lambertini, S. Martel, C. Campbell, S. Guillaume +13 more
20180 citations
Semantic Scholar
Meta-analysis of four phase III RCTs of tamoxifen, versus 3rd generation aromatase inhibitors as first-line endocrine therapy for HR+ advanced breast cancer.
J. Robertson, C. Campbell, J. Bogaerts, R. Parideans +1 more
2018Annals of Oncology0 citations Open access
Semantic Scholar
158PDAdjuvant anti-HER2 therapy, treatment-induced amenorrhea (TIA) and survival in premenopausal patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Analysis from the ALTTO trial (BIG 2-06)
M. Lambertini, C. Campbell, J. Bines, L. Korde +16 more
20170 citations Open access
Semantic Scholar
Abstract P6-01-04: Breast ultrasound and mammography and response to neoadjuvant lapatinib, trastuzumab and their combination in HER2 positive breast cancer: Results from Neo-ALTTO (BIG 1-06)
S. Di Cosimo, C. Campbell, H. Hazim, G. Curigliano +7 more
20160 citations
Semantic Scholar
Reply to A. Oguz et al.
C. O'Sullivan, E. Holmes, C. Campbell, I. Bradbury +2 more
2016Journal of Clinical Oncology0 citations
Semantic Scholar
Meta-analysis of clinical outcomes to second-line endocrine therapy for visceral and non-visceral metastases.
J. Robertson, C. Campbell, A. Di Leo, S. Johnston +2 more
20150 citations
Semantic Scholar
Phaeochromocytoma/paraganglionoma patients in a joint endocrine genetic clinic setting
Susan E. Stewart, J. Ayuk, C. Campbell, T. Cole
20100 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

E. de Azambuja×21
Invite
E. de Azambuja — researcher profile on SciRah
I. Bradbury×15
Invite
I. Bradbury — researcher profile on SciRah
M. Piccart×13
Invite
M. Piccart — researcher profile on SciRah
J. Baselga×13
Invite
J. Baselga — researcher profile on SciRah

×11

Invite

D. Fumagalli — researcher profile on SciRah

Invite

R. Gelber — researcher profile on SciRah

S. Di Cosimo×10

Invite

S. Di Cosimo — researcher profile on SciRah

Invite

S. Loi — researcher profile on SciRah

Invite

L. Korde — researcher profile on SciRah

Invite

J. Huober — researcher profile on SciRah

M. Piccart-Gebhart×6

Invite

M. Piccart-Gebhart — researcher profile on SciRah

M. Ignatiadis×6

Invite

M. Ignatiadis — researcher profile on SciRah